UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
For Registration of Certain Classes of Securities
Pursuant to Section 12(b) or (g) of the
Securities Exchange Act of 1934
MONOPAR THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
32-0463781
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
1000
Skokie Blvd., Suite 350
|
|
|
Wilmette,
Illinois
|
|
60091
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Securities to be registered pursuant to Section 12(b) of the
Act:
Title of each class to be so registered
|
|
Name of each exchange on which each class is to be
registered
|
Common Stock, par value $0.001 per share
|
|
The NASDAQ Stock Market LLC
|
If this form relates to the registration of a
class of securities pursuant to Section 12(b) of the Exchange
Act and is effective pursuant to General Instruction A.(c) or (e),
check the following box.
☒
If this
form relates to the registration of a class of securities pursuant
to Section 12(g) of the Exchange Act and is effective pursuant
to General Instruction A.(d) or (e), check the following
box. ☐
If this
form relates to the registration of a class of securities
concurrently with a Regulation A offering, check the following box.
☐
Securities Act
registration statement file number to which this form relates (if
applicable): 333-233303
Securities to be
registered pursuant to Section 12(g) of the Act: None
Item 1.
Description
of Registrant’s Securities to be
Registered.
Monopar
Therapeutics Inc. (the “Registrant”) hereby
incorporates by reference the description of its Common Stock,
$0.001 par value per share, to be registered hereunder, contained
under the heading “Description of Capital Stock” in the
Registrant’s Registration Statement on Form S-1 (File No.
333-233303), as originally filed with the Securities and Exchange
Commission (the “Commission”) on August 15, 2019, as
amended (the “Registration Statement”). In addition,
all of the above-referenced descriptions included in any prospectus
relating to the Registration Statement filed with the Commission
pursuant to Rule 424(b) under the Securities Act of 1933, as
amended, shall be deemed to be incorporated by
reference.
Item 2. Exhibits.
Pursuant to the
Instructions as to Exhibits, no exhibits are filed herewith or
incorporated herein by reference.
Signature
Pursuant to the
requirements of Section 12 of the Securities Exchange Act of
1934, the Registrant has duly caused this registration statement to
be signed on its behalf by the undersigned, thereto duly
authorized.
|
Monopar
Therapeutics Inc
|
|
|
|
|
|
Date: September 30,
2019
|
By:
|
/s/
Chandler D.
Robinson
|
|
|
|
Name:
Chandler D.
Robinson
|
|
|
|
Title:
Chief
Executive Officer
|
|